Highlight Therapeutics Sl Is A Clinical Stage Biotechnology Company Based In Valenciaspainfounded In 2010The Company Focuses On Immuno Oncology And Dermato Oncologydeveloping Innovative Therapies That Activate The Immune System To Combat Cancerparticularly Skin Cancers The Company S Lead Productbo 112Is An Intra Lesional Rna Based Therapy Designed To Stimulate A Systemic Immune Response Through Direct Tumor Injectionit Targets Basal Cell Carcinoma And Other Skin Malignancieswith Ongoing Clinical Trials Assessing Its Safety And Efficacy In Patients With Resectable Tumorsbo 112 Works By Mimicking Viral Infections Within Tumorstriggering Both Innate And Adaptive Immune Responsesand Is Intended To Be Used Alongside Checkpoint Inhibitors Or As A Standalone Treatment Led By Ceo Marisol Quinterohighlight Therapeutics Operates From The Parque Cienta Fico Universidad De Valenciathe Company Is Privately Held And Has Received Investments From Columbus Venture Partners Since 2019Highlight Therapeutics Is Committed To Advancing Next Generation Immunotherapies To Address The Growing Need For Effective Treatments In The Field Of Oncology
